Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca plc, Sanofi S.A., Merck & Co., Inc., Boehringer Ingelheim International GmbH, and Zealand Pharma A/S are global key players in the market
(1) To reduce the risk of CV death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure
[DOI] [PMC free article] [PubMed] [Google Scholar] 106.Watanabe M., Houten S.M., Mataki C., Christoffolete M.A., Kim B.W., Sato H., Messaddeq N., Harney J.W., Ezaki O., Kodama T., et al
Diet and exercise is still first line but when it fails, GLP-1 receptor agonists offer a medically supported solution
Of the total weight lost, approximately 45.2% came from lean mass rather than fat